


Ridaforolimus

Chemical Properties

CAS No. :	572924-54-0
Formula:	C53H84NO14P
Molecular Weight:	990.21
Storage:	Powder: -20°C for 3 years Actual storage temperature shall be subject to the COA.



Biological Description

Description	Ridaforolimus (AP23573) is a small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to and inhibits the mammalian target of rapamycin (mTOR), which may result in cell cycle arrest and, consequently, the inhibition of tumor cell growth and proliferation. Upregulated in some tumors, mTOR is a serine/threonine kinase involved in regulating cellular proliferation, motility, and survival that is located downstream of the PI3K/Akt signaling pathway.
Targets(IC50)	Antibacterial, Autophagy, mTOR
In vitro	Deforolimus exhibits significant antitumor activity in a dose-dependent manner in mice bearing xenografts of PC-3 (prostate), HCT-116 (colon), MCF7 (breast), PANC-1 (pancreas), or A549 (lung) cancers. It inhibits the mTOR signaling pathway in the SK-LMS-1 xenograft model associated with the inhibition of tumor growth.
In vivo	Deforolimus exhibits dose-dependent inhibition of S6 and 4E-BP1 phosphorylation in HT-1080 cells, with IC50 values of 0.2 nM and 5.6 nM, respectively, and EC50 values of 0.2 nM and 1.0 nM, respectively. It leads to a reduction in cell size, an increase in G1 phase cells, and inhibition of glucose uptake, with an EC50 range of 0.1-1 nM. Demonstrating significant antiproliferative activity across a spectrum of cell lines, Deforolimus has EC50 values ranging from 0.2 to 2.3 nM. It effectively and selectively inhibits VEGF production in a dose-dependent manner, with an EC50 of ~0.1 nM. When combined with MEK inhibitors CI-1040 or PD0325901 on human lung cancer cell lines, Deforolimus synergizes, leading to a dose-dependent reduction in cell proliferation rather than an increase in cell apoptosis. This combination, after a 24-hour treatment, results in a 40% inhibition of ribosomal synthesis and a decrease in the ratio of polysomes to monosomes. Notably, Deforolimus significantly inhibits the growth of human NSCLC cell lines (except for H157 cells) with IC30 values between 2.45-8.83 nM, but its effect on H157 cells shows an IC30 >20 nM. Treating A549, H1703, and H157 cells (excluding H1666 cells with mTORC1-resistant mutations) with 2.8-5.9 nM Deforolimus results in dephosphorylation of p70S6KThr389 and increased phosphorylation levels of pAKTser473 and pAKTThr308 in A549 and H1703 cells.
Kinase Assay	HT-1080 cells are treated with increasing concentrations of Deforolimus (0-100 nM) for 2 hours, prior to harvest. Cellular lysates are extracted in denaturing lysis buffer, resolved on SDS-PAGE and transferred to PVDF membranes. After blocking, membranes are incubated with primary antibodies for 1 hour, followed by appropriate HRP-conjugated

Kinase Assay	secondary antibodies for 1 hour at room temperature. Immunoreactive proteins are detected using enhanced chemiluminescence and autoradiography performed by exposure to X-ray film. IC50 is determined by the inhibition of levels of phosphorylated ribosomal protein S6 (p-S6) and 4E-BP1 (p-4E-BP1).
Cell Research	Cell lines: Colo205,H1755,H1395,H1666,A549,H157,and H1703 cells. Concentrations: Dissolved in ethanol,final concentrations ~ 1 µM. Method: Cells are seeded at 2-3 ×10 ⁴ /mL,and serial dilutions of Deforolimus are added after 2 hours,for at least three cell doublings (72-120 hours).Deforolimus effects are measured by the CellTiter 96 Aqueous nonradioactive cell proliferation assay and Sulforhodamine B assays.
Animal Research	Animal Models: Male and female athymic NCr-nu mice with xenografts established by subcutaneous implantation of PC-3,A549,HCT-116,MCF7,PANC-1 and SK-LMS-1 tumors. Formulation: Dissolved in ethanol,and diluted in a vehicle of 4% ethanol,5% Tween 80, and 5% propylene glycol. Dosages: ~10 mg/kg. Administration: Intraperitoneally injection

Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 160 mg/mL (161.58 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (4.04 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.0099 mL	5.0494 mL	10.0989 mL
5 mM	0.202 mL	1.0099 mL	2.0198 mL
10 mM	0.101 mL	0.5049 mL	1.0099 mL
50 mM	0.0202 mL	0.101 mL	0.202 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Rivera VM, et al. Mol Cancer Ther, 2011, 10(6), 1059-1071.

Chen W, Liao Y, Sun P, et al. Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma. Journal of Translational Medicine. 2024, 22(1): 1-19.

Legrier ME, et al. Cancer Res, 2007, 67(23), 11300-11308.

Gayle SS, et al. Anticancer Agents Med Chem, 2012, 12(2), 151-162.

Squillace RM, et al. Int J Oncol, 2012, 41(2), 425-432.

Floc'h N, et al. Cancer Res, 2012, 72(17), 4483-4493.

Brandt M, et al. mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. Cell Metab. 2018 Jan 9;27(1):118-135.e8.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481